On 12 October 2026 the Union Health Secretary, Smt. Punya Salila Srivastava, wrote to the Chief Secretaries of every State and Union Territory asking them to ensure that clinical establishments prominently display the rates they charge.
A letter. Not a notification, not an order, not a penalty. For a requirement that has been in the rules since 2012, that may look like weak administration. It is not. It is an accurate expression of how much power the Union Government actually has over this subject, and understanding why is the whole value of this topic.
Why the Centre has to ask
Public health and hospitals are a State subject. They sit in the State List of the Seventh Schedule, which means Parliament has no general competence to legislate on them.
The Clinical Establishments (Registration and Regulation) Act, 2010 exists anyway, and it exists by a route that examiners love: Article 252. Under Article 252(1), if the legislatures of two or more States pass resolutions asking Parliament to legislate on a State List subject, Parliament may do so — and the resulting law applies to those States and to any other State that later adopts it by resolution. The Act received assent on 18 August 2010 and commenced on 1 March 2012.
Three consequences follow, and they are the examinable core.
First, the Act is not in force everywhere. It binds the States that requested it, the States that have since adopted it, and the Union Territories. In the rest, clinical establishments are regulated under the respective State or UT frameworks — several of which, as the Health Secretary's letter notes, contain their own rate-display provisions.
Second, even where the Act applies, implementation and enforcement rest with the State. The registering authorities, the inspections and the penalties are State machinery.
Third, and therefore, the Union Government's available instrument is persuasion. A letter from a Secretary to Chief Secretaries, asking them to review compliance and issue advisories, is not the Centre declining to act firmly. It is the Centre acting at the outer edge of its competence.
What Rule 9 actually requires — two very different things
The provision in question is Rule 9 of the Clinical Establishments (Central Government) Rules, 2012, and it contains two limbs that are constantly conflated. Separating them is essential.
Rule 9(i) is a disclosure requirement. Clinical establishments must display the rates charged for each type of service and facility at a conspicuous place, in the local language as well as in English. It caps nothing. It only requires that the price be knowable.
Rule 9(ii) is a price-control provision. It requires establishments to charge for each procedure and service within the range of rates determined and issued by the Central Government in consultation with State Governments.
The Health Secretary's letter is about the first. It asks for compliance with display obligations so that patients and attendants can understand the likely cost of treatment, plan their expenditure, and avoid billing disputes. It does not purport to fix any rate.
That restraint is deliberate, because the second limb is in court.
The same rule, challenged from both directions
This is the most interesting feature of the topic, and almost no coverage sets it out.
Rule 9(ii) is being litigated simultaneously by those who want it struck down and those who want it enforced.
On one side, provider bodies — the Association of Healthcare Providers (India) and the All India Ophthalmological Society among them — have challenged Rule 9(ii) as ultra vires the parent Act, arguing that the 2010 Act does not authorise the Central Government to fix rates for private medical practice. In April 2024 the Supreme Court itself pressed the point in open court, asking how the government could prescribe a uniform rate for services provided by private hospitals and doctors, and drawing an analogy with fixing uniform fees for lawyers. Notice was issued on the provider petition later in 2024.
On the other side, a separate petition seeks a direction to enforce Rules 9(i) and 9(ii) across the States, on which the Court issued notice in 2025.
The Union Government, in its counter-affidavit, has defended Rule 9(ii) as constitutionally valid, arguing that standardised rate ranges curb price gouging, excessive charging and arbitrary inflation of medical bills, and grounding the power in the State's obligation under Article 47 to raise the level of nutrition and public health.
So the legal position is a genuine standoff: a directive principle (Article 47) against a fundamental right to carry on a profession (Article 19(1)(g)), over a rule framed under an Article 252 statute. The matters were pending at last report, and no final judgment has been delivered — which is exactly why a Secretary's letter about display was the available move, while rate-setting waits for the Court.
What disclosure can and cannot do
It is worth being precise about the mechanism, because "transparency" is often asserted rather than explained.
Displaying rates does three real things. It makes comparison possible between establishments for elective procedures. It converts a dispute that would otherwise arise after treatment, when the patient has no leverage, into a decision taken before it. And it creates a documentary standard against which a bill can be contested.
It also has a hard limit, and the limit is where the harm concentrates. Nobody comparison-shops a cardiac arrest. In an emergency admission, an unconscious patient or a frightened family has no capacity to choose on price, and a displayed tariff board does not help them. Catastrophic health expenditure in India arises disproportionately from exactly those episodes — unplanned, urgent, inpatient.
So Rule 9(i) protects the elective patient reasonably well and the emergency patient hardly at all. That is not an argument against it; disclosure is cheap, lawful and useful. It is an argument for being honest about what it is: a consumer-information measure, not a financial-protection measure. Financial protection comes from insurance coverage and from price regulation — the latter being what Rule 9(ii) was meant to supply and what is currently sub judice.
The same distinction runs through the pricing of medicines, where the government capped a trade margin rather than a price, leaving the manufacturer's base price untouched — the instrument examined in a 170% mark-up capped at 30%. In both cases the state has reached for the mildest effective lever available to it.
The medical-visa provision, which is a trade measure
One request in the letter is easy to skim past and is not really about Indian patients at all.
States and UTs have been asked to encourage the prominent display of package rates offered to foreign patients travelling to India on Medical or Ayush Visas, so that international patients can make informed choices and pricing grievances are minimised — and, as the release puts it, so as to strengthen India's position as a trusted destination for medical and Ayush care.
India's medical-value-travel proposition rests on cost predictability as much as on clinical quality. A foreign patient cannot evaluate an Indian hospital's reputation easily, but can compare a published package price. Opaque pricing is therefore a competitive liability in that market, and a disclosure norm is an export-promotion instrument wearing a patient-rights label. Both readings are true, and noticing the second is what separates a careful answer.
The pattern this belongs to
Step back and the shape is familiar. A rule exists. It is fourteen years past the parent Act and more than a decade past the rules. It has never been uniformly enforced, and the Union Government's method of pursuing it in 2026 is to write to Chief Secretaries requesting their personal attention.
That is the same gap between a norm on paper and a norm in force that the Supreme Court addressed in the accessibility rules — where guidelines dressed as mandatory standards were held ultra vires and the replacement standards are still in draft, as set out in ten years of Sugamya Bharat and still no yardstick. It is also the gap that a working register closes in the health professions, which is why a scannable national register for 56 allied health professions matters more than its announcement suggested.
The lesson generalises, and it is worth carrying into any question about Indian regulation: the existence of a rule tells you very little. Ask who registers, who inspects, who penalises, and whether the subject is a State one. For clinical establishments, the answers are: a State authority, State inspectors, State penalties, and yes.
🔑 Revision block
- What: Union Health Secretary Punya Salila Srivastava wrote to Chief Secretaries of all States and UTs on 12 October 2026, urging prominent display of healthcare service rates by clinical establishments.
- Constitutional basis: public health and hospitals are a State subject; Parliament enacted the Clinical Establishments (Registration and Regulation) Act, 2010 under Article 252(1) on resolutions of State legislatures. Assent 18 August 2010; commenced 1 March 2012.
- Consequence of Article 252: the Act applies to the requesting States, later-adopting States and the Union Territories — not automatically to all States. Elsewhere, State/UT frameworks govern.
- Rule 9, Clinical Establishments (Central Government) Rules, 2012 — two limbs:
- Rule 9(i) — disclosure: display rates for each service and facility at a conspicuous place, in the local language and English. Caps nothing.
- Rule 9(ii) — price control: charge within the range of rates determined by the Central Government in consultation with State Governments.
- Litigation (pending): provider bodies including the Association of Healthcare Providers (India) and the All India Ophthalmological Society challenge Rule 9(ii) as ultra vires the parent Act; a separate petition seeks enforcement of Rules 9(i) and 9(ii); the Court in 2024 questioned fixing uniform rates for private practice. The Centre defends the rule under Article 47.
- The clash: Article 47 (directive principle on public health) against Article 19(1)(g) (right to practise a profession).
- Also requested: display of package rates for foreign patients on Medical and Ayush Visas — a medical-value-travel measure as much as a patient-rights one.
- Enforcement reality: registration, inspection and penalties are State functions; the Union's instrument is an advisory letter.
- Exam hook: disclosure is not price control. Rule 9(i) helps the elective patient compare and contest; it does almost nothing for the emergency patient, which is where catastrophic health expenditure concentrates.
🎯 Practice MCQs
Q1. Parliament was able to enact the Clinical Establishments (Registration and Regulation) Act, 2010 because: (a) Public health was moved to the Union List by amendment (b) The Act was enacted under the residuary power in Article 248 (c) State legislatures passed resolutions under Article 252 requesting it (d) Health is a Concurrent List subject
→ (c) Public health and hospitals are in the State List, so Article 252(1) was the route; the law binds requesting and later-adopting States, plus the Union Territories.
Q2. A law made under Article 252 applies to: (a) The States that passed the resolutions and any State that later adopts it (b) All States automatically (c) Only Union Territories (d) All States, but only for two years
→ (a) Which is why clinical establishments in non-adopting States are regulated under their own State frameworks instead.
Q3. Rule 9(i) of the Clinical Establishments (Central Government) Rules, 2012 requires establishments to: (a) Charge within a government-determined range of rates (b) Display rates for each service in a conspicuous place, in the local language and English (c) Publish annual audited accounts (d) Register with the National Medical Commission
→ (b) It is a disclosure requirement and caps nothing. The rate-range obligation is the separate second limb.
Q4. Rule 9(ii) of the same Rules has been challenged by provider bodies on the ground that: (a) It violates the right to privacy of patients (b) It requires display only in English (c) It applies retrospectively (d) It is ultra vires the parent Act, which does not authorise rate-fixing for private practice
→ (d) The Supreme Court in 2024 also questioned how uniform rates could be fixed for private hospitals and doctors.
Q5. The Union Government has defended Rule 9(ii) by invoking: (a) Article 47, on the State's duty to improve public health (b) Article 21, on the right to life (c) Article 300A, on property (d) Article 301, on freedom of trade
→ (a) Setting a directive principle against the Article 19(1)(g) right to carry on a profession.
Q6. In States where the 2010 Act does not apply, clinical establishments are regulated: (a) By the National Medical Commission directly (b) Under no framework at all (c) Under the respective State or Union Territory frameworks (d) By the Consumer Protection Act exclusively
→ (c) Several such State frameworks contain their own rate-display provisions, as the Health Secretary's letter notes.
Q7. The principal limitation of a rate-display requirement is that it: (a) Cannot be printed in regional languages (b) Does little for emergency admissions, where price comparison is impossible (c) Applies only to government hospitals (d) Requires patients to pay in advance
→ (b) Catastrophic health expenditure arises disproportionately from unplanned, urgent inpatient episodes, where a displayed tariff cannot guide choice.
Q8. The letter also asked States to encourage display of package rates for: (a) Patients covered under Ayushman Bharat (b) Senior citizens above seventy (c) Government employees under CGHS (d) Foreign patients travelling on Medical and Ayush Visas
→ (d) A measure aimed at India's medical-value-travel position as much as at patient information.
Q9. Enforcement of the Clinical Establishments Act rests with: (a) The States and Union Territories (b) The Union Ministry of Health and Family Welfare (c) The National Health Authority (d) The Central Consumer Protection Authority
→ (a) Registration, inspection and penalties are State functions, which is why the Centre's instrument here is an advisory letter.
Q10. Which pair correctly matches the instrument to its effect? (a) Rule 9(i) fixes a ceiling price; Rule 9(ii) requires disclosure (b) Both limbs fix prices (c) Rule 9(i) requires disclosure; Rule 9(ii) requires charging within a government-set range (d) Both limbs are advisory only
→ (c) Conflating disclosure with price control is the commonest error in this topic, and the two limbs are in very different legal positions.
📋 How this gets asked (PYQ pattern)
This topic is unusually rich for CDS and OTA papers because it joins a constitutional provision, a statute, a subordinate rule and live litigation.
The first and most valuable hook is Article 252. It is one of only a few routes by which Parliament may legislate on a State subject, and candidates confuse it constantly with Article 249 (Rajya Sabha resolution on a State subject in the national interest), Article 250 (during a Proclamation of Emergency) and Article 253 (to implement an international agreement). Learn the four together, because a question on any one of them usually offers the other three as distractors. Article 252 is the State-initiated route, and its distinguishing feature is that the law binds only consenting States.
The second is the subject list. Public health and hospitals are in the State List. A statement placing health in the Concurrent List is a standard false option — although several health-adjacent entries, such as population control and family planning, and medical education, genuinely are concurrent. Precision matters.
The third is Rule 9's two limbs. Disclosure versus rate range. Expect a question that attributes rate-fixing to Rule 9(i).
The fourth is the constitutional clash, which is where a written answer earns its marks: Article 47 as a directive principle supporting price regulation, against Article 19(1)(g) as a fundamental right resisting it, with the courts yet to settle the matter. Being able to name both provisions and state that the litigation is pending is a complete, current answer.
For an interview, the sharpest thing to say is the federal point. The Union Government did not send a letter because it was being polite. It sent a letter because health is a State subject, the Act runs on State consent, and enforcement belongs to State authorities. Recognising an advisory as the limit of competence rather than a failure of will is the mark of someone who understands Indian federalism.
Preparing for CDS/OTA? With any regulation, ask four questions: who registers, who inspects, who penalises, and whose List the subject is on. The answers predict how much the Centre can actually do. Build the base with our CDS/OTA study material and the polity section, follow the daily CDS current affairs, and prepare with our faculty in the upcoming Cavalier courses in Delhi.
✍️ Written by The Cavalier Faculty Desk — Polity & Social Justice, at The Cavalier. Reviewed by the Cavalier Faculty Desk.